Sorafenib alone vs. sorafenib plus GEMOX as 1(st)-line treatment for advanced HCC: the phase II randomised PRODIGE 10 trial.

Assenat E, Pageaux GP, Thézenas S, Peron JM, Bécouarn Y, Seitz JF, Merle P, Blanc JF, Bouché O, Ramdani M, Poujol S, de Forges H, Ychou M, Boige V

Open source

DOI: 10.1038/s41416-019-0443-4
Published: 2019 Apr
Container: British journal of cancer
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1038/s41416-019-0443-4,
  title = {Sorafenib alone vs. sorafenib plus GEMOX as 1(st)-line treatment for advanced HCC: the phase II randomised PRODIGE 10 trial.},
  author = {Assenat E and Pageaux GP and Thézenas S and Peron JM and Bécouarn Y and Seitz JF and Merle P and Blanc JF and Bouché O and Ramdani M and Poujol S and de Forges H and Ychou M and Boige V},
  year = {2019},
  journal = {British journal of cancer},
  doi = {10.1038/s41416-019-0443-4},
  url = {https://doi.org/10.1038/s41416-019-0443-4}
}

RIS

TY  - JOUR
TI  - Sorafenib alone vs. sorafenib plus GEMOX as 1(st)-line treatment for advanced HCC: the phase II randomised PRODIGE 10 trial.
AU  - Assenat E
AU  - Pageaux GP
AU  - Thézenas S
AU  - Peron JM
AU  - Bécouarn Y
AU  - Seitz JF
AU  - Merle P
AU  - Blanc JF
AU  - Bouché O
AU  - Ramdani M
AU  - Poujol S
AU  - de Forges H
AU  - Ychou M
AU  - Boige V
PY  - 2019
JO  - British journal of cancer
DO  - 10.1038/s41416-019-0443-4
UR  - https://doi.org/10.1038/s41416-019-0443-4
ER  -

APA

E, A., GP, P., S, T., JM, P., Y, B., JF, S., P, M., JF, B., O, B., M, R., S, P., H, D. F., M, Y., & V, B. (2019). Sorafenib alone vs. sorafenib plus GEMOX as 1(st)-line treatment for advanced HCC: the phase II randomised PRODIGE 10 trial.. British journal of cancer. https://doi.org/10.1038/s41416-019-0443-4

Source records

pubmed · retrieved 2026-09-26T07:41:00.191Z